SHELLY FOWLER: Open Payments
NPI 1598954208 · LEEDS, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,202 in 60 payments from 13 companies in 2025. Trend: 2023 $2,889 · 2024 $2,822 · 2025 $1,202
Food & beverage: $1,202
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 14 | $344 |
| Regeneron Healthcare Solutions, Inc. | 14 | $250 |
| GlaxoSmithKline, LLC. | 11 | $161 |
| Amgen Inc. | 5 | $110 |
| GENZYME CORPORATION | 3 | $61 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $58 |
| GC Biopharma USA, Inc. | 2 | $49 |
| PFIZER INC. | 3 | $49 |
| LEO Pharma Inc. | 2 | $46 |
| Pharming Healthcare, Inc. | 1 | $28 |
Products named: DUPIXENT, FASENRA, TEZSPIRE, TRELEGY ELLIPTA, AIRSUPRA, TAKHZYRO, ALYGLO, CIBINQO.
Industry payments across MA — which companies pay providers there.
